ATE429902T1 - Pharmazeutische formulierungen mit fenofibrat mit verbesserter bioverfügbarkeit - Google Patents

Pharmazeutische formulierungen mit fenofibrat mit verbesserter bioverfügbarkeit

Info

Publication number
ATE429902T1
ATE429902T1 AT05258082T AT05258082T ATE429902T1 AT E429902 T1 ATE429902 T1 AT E429902T1 AT 05258082 T AT05258082 T AT 05258082T AT 05258082 T AT05258082 T AT 05258082T AT E429902 T1 ATE429902 T1 AT E429902T1
Authority
AT
Austria
Prior art keywords
fenofibrate
pharmaceutical formulations
improved bioavailability
polethylene
polyethylene glycol
Prior art date
Application number
AT05258082T
Other languages
English (en)
Inventor
Itzhak E Lerner
Vered Rosenberger
Moshe Flashner-Barak
Anna Drabkin
Naomi Moldavski
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE429902T1 publication Critical patent/ATE429902T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT05258082T 2005-12-28 2005-12-28 Pharmazeutische formulierungen mit fenofibrat mit verbesserter bioverfügbarkeit ATE429902T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05258082A EP1803441B1 (de) 2005-12-28 2005-12-28 Pharmazeutische Formulierungen mit Fenofibrat mit verbesserter Bioverfügbarkeit

Publications (1)

Publication Number Publication Date
ATE429902T1 true ATE429902T1 (de) 2009-05-15

Family

ID=36260529

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05258082T ATE429902T1 (de) 2005-12-28 2005-12-28 Pharmazeutische formulierungen mit fenofibrat mit verbesserter bioverfügbarkeit

Country Status (7)

Country Link
EP (1) EP1803441B1 (de)
AT (1) ATE429902T1 (de)
DE (1) DE602005014258D1 (de)
DK (1) DK1803441T3 (de)
ES (1) ES2325450T3 (de)
PL (1) PL1803441T3 (de)
PT (1) PT1803441E (de)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FR2730231B1 (fr) 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
FR2737121B1 (fr) 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6814977B1 (en) 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6719999B2 (en) 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
EP1322289B1 (de) * 2000-09-20 2007-07-25 Jagotec AG Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
IL164152A0 (en) 2002-03-26 2005-12-18 Teva Pharma Drug microparticles
KR20130103818A (ko) * 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 피브레이트를 포함하는 고형 제제

Also Published As

Publication number Publication date
ES2325450T3 (es) 2009-09-04
DK1803441T3 (da) 2009-08-03
PT1803441E (pt) 2009-06-08
EP1803441A1 (de) 2007-07-04
PL1803441T3 (pl) 2009-10-30
HK1104790A1 (en) 2008-01-25
DE602005014258D1 (de) 2009-06-10
EP1803441B1 (de) 2009-04-29

Similar Documents

Publication Publication Date Title
ES2525410T3 (es) Composiciones y métodos para el tratamiento de enfermedades hiperproliferativas dérmicas
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
ATE478840T1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
NO20071914L (no) Kontrollert avleveringssystem
DE122011100049I1 (de) Stabile pharmazeutische Losungsformulierungen fur unter Druck stehende Inhaliergerate fur die Verabreichung abgemessener Dosen.
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
DE602005010788D1 (de) Pharmazeutische Zusammensetzungen zur sicheren Verabreichung von bei der Behandlung von Drogenabhängigkeit verwendeten Arzneimitteln
TW200716206A (en) Unitary pharmaceutical dosage form
CY1117021T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν νιλοτινιβη ή αλας αυτης
ECSP034868A (es) Cápsulas para inhalación
NI200900126A (es) Producto de combinacion para combatir parásitos en animales.
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
ATE366105T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nsaid und einen prostaglandin
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
BRPI0620229A8 (pt) formulação
AR039232A1 (es) Una formulacion farmaceutica que comprende al menos un compuesto seleccionado del grupo formado por hipnoticos no barbituricos y no benzodiacepinicos, y melatonina
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
BRPI0520821A2 (pt) formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
WO2004064757A3 (en) Absorption enhancing agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties